Celldex Therapeutics (CLDX) Gains from Sales and Divestitures (2012 - 2020)
Celldex Therapeutics (CLDX) recorded quarterly Gains from Sales and Divestitures of $1110.0 in Q4 2020, down 50.0% quarter-over-quarter from $2220.0 in Q4 2019, and down 50.0% on a YoY basis from $2220.0 in Q1 2020.
Celldex Therapeutics (CLDX) Gains from Sales and Divestitures (2012 - 2020) Analysis & Trends
Celldex Therapeutics' Gains from Sales and Divestitures history runs 9 years deep, the most recent figure standing at $1110.0 for Q4 2020.
- In Q4 2020, Gains from Sales and Divestitures fell 50.0% year-over-year to $1110.0; the TTM figure through Dec 2020 stood at $1110.0 (down 50.0% YoY), while the FY2020 annual figure was $1110.0, down 50.0% from the prior year.
- Gains from Sales and Divestitures was $1110.0 for Q4 2020 at Celldex Therapeutics, down from $2220.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $19500.0 in Q4 2016 to a low of $1110.0 in Q4 2020.
- Historically, Gains from Sales and Divestitures has averaged $8388.8 across 5 years, with a median of $2449.0 in 2018.
- The sharpest annual moves came in 2018 and 2019: Gains from Sales and Divestitures slumped 85.3% in 2018, then slipped 9.35% in 2019.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $19500.0 in 2016, then fell by 14.54% to $16665.0 in 2017, then plunged by 85.3% to $2449.0 in 2018, then retreated by 9.35% to $2220.0 in 2019, then tumbled by 50.0% to $1110.0 in 2020.
- The last three Gains from Sales and Divestitures figures came in at $1110.0 (Q4 2020), $2220.0 (Q4 2019), and $2449.0 (Q4 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Celldex Therapeutics | 2.16 Bn | 2.16 Bn | -1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 1,110.00 |
| Dec 31, 2020 | 1,110.00 |
| Dec 31, 2019 | 2,220.00 |
| Dec 31, 2019 | 2,220.00 |
| Dec 31, 2018 | 2,449.00 |
| Dec 31, 2018 | 2,449.00 |
| Dec 31, 2017 | 16,665.00 |
| Dec 31, 2017 | 16,665.00 |
| Dec 31, 2016 | 19,500.00 |
| Dec 31, 2016 | 19,500.00 |
| Dec 31, 2015 | 26,500.00 |
| Dec 31, 2015 | 26,500.00 |
| Dec 31, 2014 | 12,000.00 |
| Dec 31, 2014 | 12,000.00 |
| Dec 31, 2013 | 12,000.00 |
| Dec 31, 2013 | 12,000.00 |
| Dec 31, 2012 | 12,000.00 |
| Dec 31, 2012 | 12,000.00 |
| Jun 30, 2012 | 6,000.00 |
| Jun 30, 2012 | 6,000.00 |